Out-Licensing-Oriented Patent Strategy: A Case Study of Pfizer–3SBio Bispecific Antibody SSGJ-707

Chinese Biopharmaceutical Association - USA, China Branch (CBA-China)Always committed to building a bridge connecting China and the U.S., integrating Eastern and Western academia and industry. Based on the global wave of biopharmaceutical innovation, focusing on industry pain points and future trends, we willMay 8-10InWuxi International Convention CenterHold2026 CBA-China Annual Conference in China。The conference was titled "Breaking the Deadlock, Symbiosis for a Healthy Future —— Addressing Global Changes, Building a New Ecosystem for Drug Innovation and Accessibility" as the theme, bringing together 260+ authoritative guests from home and abroad, 4000+ industry elites, and meticulously crafting 13 parallel forums, coveringEarly Development、Clinical Translation、Global Registration、CGT、ADC、AI Drug Discovery、Investment and Financing BDCovering all core sectors of the entire industrial chain. From in-depth analysis of cutting-edge technologies to interpretation of industry policies, from project matchmaking to capital cooperation, the comprehensive agenda fully showcases the global pharmaceutical innovation ecosystem, offering industry peers a high-standard, all-encompassing, and deeply informative annual intellectual feast.

Li Caihui, IP Head of Junshi BiosciencesWill attend this conference and on the morning of May 10th "Intellectual Property (IP) DiscussionForum Keynote Speech Report:Outward Licensing-Oriented Patent Layout: A Case Study of Pfizer–3SBio Bispecific Antibody SSGJ-707。

Guan Ningning, with years of experience in eCTD software training and service outsourcing, is proficient in various drug submission standards (IND, NDA, BLA, ANDA, etc.). She has led her team to complete the delivery of hundreds of eCTD/eSub projects of different submission types for regions such as CDE, FDA, EMA, and GCC.